R-Pharm is discussing the purchase of the Japanese Takeda plant in Yaroslavl – Kommersant
[ad_1]
The drug manufacturer R-Pharm is negotiating the purchase of the Japanese Takeda plant in Yaroslavl, reports Vedomosti with reference to sources. According to them, binding documents have not yet been signed, but the parties have reached agreements in principle and are discussing the value of the asset. The amount is not given.
As one of the interlocutors of the newspaper clarified, Takeda wants to sell the enterprise, including because of the sanctions, but does not intend to leave Russia. Another Vedomosti source claims that the purchase of the Japanese company’s plant is also being considered by Viktor Kharitonin’s Pharmstandard, but negotiations with it are at a less advanced stage.
A representative of R-Pharma told Vedomosti that the company could not comment on transactions until they were closed. Takeda’s Russian office declined to comment. The representative of “Pharmstandard” did not comment on the information.
According to SPARK-Interfax, in 2021, the revenue of Takeda Pharmaceutical, the Russian legal entity of the company, amounted to 21.9 billion rubles, which is 22% more year-on-year. The Takeda plant in Yaroslavl was launched back in 2013. Its capacity is 90 million ampoules and more than 3 billion tablets per year. The company produces drugs prescribed for oncological, gastroenterological, neurological and rare diseases.
The fact that Takeda is considering options for the sale of its Russian plant, where more than €117 million has been invested, became known back in April. Foreign companies are forced to reduce their presence in the Russian Federation under political pressure, although the pharmaceutical industry is not subject to sanctions. This may lead to a washout of innovative drugs from the local market, experts warn.
Details – in the material “Kommersant” “Takeda is here for the time being”.
[ad_2]
Source link
